Seattle Genetics, Inc.

Oncogen

Henry Perry Fell, Jr

Alan F Wahl

Clay B Siegall

Joseph A Francisco

Margit Ann Gayle

The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.

Methods for augmenting an immune response using anti-CD40 antibodies

Methods for the treatment of cancer using anti-CD40 antibodies

Methods for treating immune disorders or cancer with anti-CD40 antibodies

Recombinant anti-CD40 antibody and uses thereof

Methods for the treatment and prevention of cancer using anti-CD40 antibodies

Nucleic acids encoding anti-CD40 proteins and methods of producing recombinant anti-CD40 proteins

The present invention relates to methods of providing a targeted, amplified antitumor immune response using antibody-based fusion proteins. More specifically, the invention relates to the use of antibody-based fusion proteins comprising an immunoglobulin portion capable of binding to a tumor antigen linked to a biologically active lymphokine. The immunoglobulin portion targets the fusion protein to the site of the tumor cells and the lymphokine portion stimulates the proliferation of immune T cells at the site of the tumor cells, thereby amplifying the anti-tumor immune response. In preferred embodiments of the invention, the immunoglobulin portion of the fusion protein is derived from the L6 monoclonal antibody and/or the lymphokine is interleukin-2.

Therapeutic antibody based fusion proteins

The present invention relates to antibody-based fusion proteins wherein a portion of an immunoglobulin molecule is linked to a biologically active ligand. In particular embodiments of the invention, the fusion protein comprises a portion of an antibody which recognizes a cell surface antigen linked to a ligand which is a lymphokine or a cellular factor. A preferred embodiment of the fusion protein comprises the variable region of the anti-tumor monoclonal antibody L6 and an active lymphokine molecule such as IL-2. In another preferred embodiment of the present invention, the fusion protein comprises the variable region of the L6 monoclonal antibody and active platelet factor 4. The antibody-based fusion proteins of the invention may be used therapeutically to deliver biologically active ligands to a specific target cell or tissue.

Therapeutic interleukin-2-antibody based fusion proteins

Growing community of inventors

Redmond, WA, United States of America

Henry Perry Fell, Jr